Mettler-Toledo International Inc. — 2017 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2017, with fourth-quarter results included. The company supplies precision instruments and related services globally; products serve laboratory, industrial, food retailing, and process analytics markets.
Financial performance
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Net sales | $2,725.1 million | $2,508.3 million | +9% reported; +8% in local currencies |
| Gross profit margin | 57.7% | 57.2% | +0.5 percentage points |
| Earnings before taxes | $574.2 million | $504.2 million | +14% |
| Net earnings | $376.0 million | $384.4 million | -2% |
| Diluted EPS | $14.24 | $14.22 | Approximately flat |
| Cash from operating activities | $516.3 million | $460.8 million | +12% |
| Capital expenditures | $127.4 million | $124.0 million | +3% |
Fourth-quarter sales were $778.0 million versus $709.7 million a year earlier. Net earnings were $77.0 million versus $137.8 million, and diluted EPS was $2.93 versus $5.17; the 2017 quarter included the tax-reform charge described below.
Cash and cash equivalents were $148.7 million at year-end, versus $158.7 million in 2016. Total debt was $979.8 million, compared with $894.0 million; debt net of cash was approximately $831.2 million. The company had about $332.6 million available under its $800 million revolving credit facility. Working capital was $188.0 million. Operating cash flow less capital expenditures was approximately $388.9 million.
Changes and operating drivers
- Growth was broad-based: laboratory-related sales rose 11% reported, industrial-related sales rose 8%, and food retailing sales fell 3% reported.
- China was a notable growth driver: local-currency sales to external customers increased 19%; Chinese segment profit increased 23% in U.S. dollars.
- Gross margin improved, supported by favorable price realization, partly offset by business mix, foreign currency, and higher material costs.
- Segment profit increased to $656.6 million from $583.0 million. Western European segment profit declined 5% in U.S. dollars, while Chinese segment profit rose 23%.
- Research and development expense was $129.3 million, or 4.7% of sales, versus $120.0 million, or 4.8%, in 2016.
Outlook, risks, and unusual items
- Management said global market conditions were favorable in 2017 but warned of difficult 2018 comparisons following strong growth, particularly in China. No specific 2018 revenue or earnings guidance is provided in the supplied filing text.
- The 2017 tax provision included a provisional $72 million one-time charge related to the Tax Cuts and Jobs Act: $59 million expected to be paid over up to eight years and $13 million non-cash. Excluding this charge, management reported a 22% effective tax rate. The accounting was provisional and subject to finalization during 2018.
- The company acquired Biotix in 2017 for an initial $105 million cash payment, with potential additional consideration of up to $65 million; $30.7 million was estimated as contingent consideration at year-end.
- Restructuring charges were $12.8 million, versus $6.2 million in 2016. Other income included a $3.4 million gain on a Swiss facility sale. The 2016 comparison included an $8.2 million non-cash pension settlement charge.
- Key risks include international and currency exposure, volatility in China and other emerging markets, competition and margin pressure, cyber and system disruptions, supply or manufacturing interruptions, customer capital-spending weakness, tax uncertainty, debt and refinancing needs, and potential environmental liabilities. China represented 17% of sales to external customers and 35% of total segment profit in 2017.
- Management expects cash from operations and available credit to cover anticipated working capital and capital spending for the foreseeable future. It plans $40–$50 million of net investment in new or expanded manufacturing facilities over the next two years and continued share repurchases, subject to business and market conditions.
Investor facts to verify
- How the final accounting for the tax-reform charge and the 2018 tax provisions affect reported earnings and cash taxes.
- Whether China’s exceptional 2017 growth is sustainable, given the stated tough comparisons and market volatility.
- Debt maturities, credit-facility availability, covenant compliance, and the funding implications of repurchases, acquisitions, and planned capital investment.
- Biotix’s subsequent performance and the amount of any contingent consideration payable.
- Whether margin improvement and cash generation continue despite material, currency, and compensation-cost pressures.
The independent auditor issued an unqualified opinion on the financial statements and reported effective internal control over financial reporting as of December 31, 2017.